By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



P.O. Box 12878

Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-544-8600 Fax: 919-544-8697




Merck & Co.  Antifungals

Company News
SCYNEXIS, Inc. (SCYX) Receives Orphan Drug Designation For SCY-078 For The Treatment Of Invasive Aspergillus Infections 8/25/2016 8:06:52 AM
SCYNEXIS, Inc. (SCYX) Reports Second Quarter 2016 Financial Results And Provides Company Update 8/8/2016 8:20:21 AM
SCYNEXIS, Inc. (SCYX) To Present At The Canaccord Genuity Growth Conference 8/4/2016 8:30:27 AM
SCYNEXIS, Inc. (SCYX) Announces Interim Results From Phase II Study Of Oral SCY-078 In Patients With Invasive Candidiasis 8/1/2016 10:52:10 AM
SCYNEXIS, Inc. (SCYX) Announces Sale Of Cyclophilin Inhibitor Assets To Cypralis Limited 7/13/2016 8:12:34 AM
SCYNEXIS, Inc. (SCYX) To Present At Cantor Fitzgerald’s 2nd Annual Healthcare Conference 7/6/2016 8:00:07 AM
SCYNEXIS, Inc. (SCYX) Initiates Enrollment Of The Phase II Study Of SCY-078 In Vulvovaginal Candidiasis 12/2/2015 7:46:07 AM
SCYNEXIS, Inc. Reports Third Quarter 2015 Financial Results And Provides Company Update 11/13/2015 9:17:59 AM
SCYNEXIS, Inc. (SCYX) Announces Initiation Of Phase I Clinical Trial Evaluating Intravenous Formulation Of SCY-078 11/12/2015 7:10:58 AM
SCYNEXIS, Inc. (SCYX) Appoints Eric Francois as Chief Financial Officer 11/3/2015 8:36:49 AM